Skip to main content

He helped Gilead score billions from HIV, hepatitis C drugs — now he's building a cancer fighter

During his tenure at Gilead, Norbert Bischofberger saw employment go from 25 or so to 10,000 as the company cranked up life-changing drugs fighting HIV and hepatitis C. Now he wants to build again, and Gilead Chairman John Martin is coming along, too.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.